The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

288538 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-08

Study Completion Date

2023-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multi-centre, retrospective study describing the impact of PCCM standardized implementation on healthcare management among Asthma or COPD or Asthma-COPD overlap patients in Tianjin city of China, using real world electronic medical record database collected in local health care settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China

NCT02600221

Asthma-COPD Overlap Syndrome

COMPLETED

Realize the Current Situation of COPD Patients in China

NCT03131362

Chronic Obstructive Pulmonary Disease COPD

COMPLETED

Perception of Symptom Variability in COPD

NCT01753427

Chronic Obstructive Pulmonary Disease

COMPLETED

Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China

NCT04853238

Pulmonary Disease, Chronic Obstructive

COMPLETED

Management and Healthcare Utilization of Patients With Chronic Airway Disease During the COVID-19 Epidemic

NCT04948216

Pulmonary Disease, Chronic Obstructive Asthma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center retrospective study to describe the impact of PCCM on healthcare management of Asthma or COPD or ACO patients in Tianjin healthcare big data platform database in China from Jan 01, 2015 to Dec 31, 2020. The impact of PCCM on healthcare management among Asthma or COPD or ACO patients will be explored. Analyses will be performed separately by disease, by hospitals with or without PCCM implementation, by period (pre-PCCM vs post-PCCM period) and by hospital grade. Patients enrolled into pre-PCCM period who also had post-PCCM visit(s) will be counted separately in two periods. The statistical analyses of this study will be primarily descriptive in nature and does not attempt to test any specific a priori hypotheses unless otherwise specified.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma COPD Asthma-COPD Overlap

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Of note, the following criteria will be applied separately to the pre-PCCM period and post-PCCM period.

* Asthma:

* Patients were age 18 years and older.
* Patients had Asthma diagnosis record according to the International Classification of Disease 10th edition (ICD-10) codes J45,J45.x, J46, J46.x.
* COPD:

* Patients were age 18 years and older.
* Patients had COPD diagnosis record according to the International Classification of Disease 10th edition (ICD-10) codesJ44 and J44.x (including the other clinical diagnostic records for COPD diagnosis codes: the other clinical diagnostic records will be defined as chronic bronchitis or emphysema or chronic wheeze bronchitis+ at least one of the following prescribed medicine which will be defined as ICS, LABA, LAMA, ICS/LABA, LABA/LAMA, ICS/LABA/LAMA, theophylline (sustained) , systemic glucocorticoids (IV/Oral), SAMA, SABA, SABA/SAMA).
* ACO:

* Patients were age 18 years and older.
* Patients had both COPD and Asthma diagnosis in a single record or within one year according to the International Classification of Disease 10th edition (ICD-10) codes J44, J44.x, J45,J45.x, J46 and J46.x.

Exclusion Criteria

* Asthma

* Patients with any history of diagnosis of COPD.
* Patients had new diagnosis of COPD during Asthma follow up period.
* COPD

* Patients with any history of diagnosis of Asthma or bronchiectasis, interstitial lung disease(i.e. pulmonary fibrosis).
* Patients had new diagnosis of Asthma during COPD follow up period.
* ACO • Patients with any history of diagnosis of bronchiectasis, interstitial lung disease (i.e. pulmonary fibrosis).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No